LOS ANGELES, CA / ACCESSWIRE / May 26, 2017 / BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, today announced that it will be presenting at the 7th annual LD Micro Invitational on Wednesday, June 7 at 8:30 AM PST / 11:30 AM EST. Jonathan Adams, CEO, will be giving the presentation and will be meeting with investors.
Conference participants who are interested in scheduling a meeting are encouraged to sign up through the conference's portal, or by calling Tony Schor at 847-945-2222 ext. 221.
BioVie is currently focused on developing and commercializing BIV201, its lead therapeutic candidate and novel approach to the treatment of refractory ascites due to advanced liver cirrhosis. BioVie will soon commence a Phase 2a clinical trial in six of these patients. BIV201 is a continuous ambulatory infusion of the peptide terlipressin and has Orphan drug status and patent protection in the US. Terlipressin, dosed differently, is approved in about 40 countries for other complications of liver cirrhosis arising from a similar disease pathway. Terlipressin is not available in the US and currently there are no FDA-approved drugs specifically for treating ascites which represents a significant unmet medical need.
BIV201 could become the first drug ever approved by the FDA for treating refractory ascites due to liver cirrhosis, a life-threatening condition which affects about 10,000 Americans. The condition results primarily from hepatitis, alcoholism, and nonalcoholic steatohepatitis (NASH) linked to fatty liver disease and obesity. Ascites is a common complication of advanced liver cirrhosis and an estimated 40% of patients die within two years of diagnosis. Certain drugs approved for other uses may provide initial relief, but patients often fail to respond to them as ascites worsens. US treatment costs for liver cirrhosis, including ascites and other complications, are estimated at more than $4 billion annually.
"This year, not only do we have a record number of companies making their LD Micro debuts, but a record number of companies presenting for the first time in their company's history" stated Chris Lahiji, President of LD Micro. "LD has established itself as the one venue that brings the most influential players from all segments of the market under one roof."
The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 180 companies in the small / micro-cap space.
View BioVie Inc. profile here: https://www.ldmicro.com/profile/BIVI
Profiles powered by LD Micro - News Compliments of Accesswire.
About BioVie, Inc.
BioVie Inc. is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company is currently focused on developing and commercializing BIV201, a novel approach to the treatment of ascites due to chronic liver cirrhosis. In March 2017, BioVie received notification from the FDA that it could initiate a Phase 2a US clinical trial. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, and alcoholism. It has Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites. For more information about BioVie and BIV201, please visit our website: www.biovieinc.com.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.
For those interested in attending, please contact David Scher at [email protected] or visit www.ldmicro.com for more information.
BioVie Contact:
Tony Schor
Investor Awareness, Inc.
847.945.2222 ext. 221
[email protected]
SOURCE: BioVie Inc.